ArTec, Inc., Of Reno, Nevada Announces Completing Its Patent Goals and Has Received the Final Patents from Canada and Western Europe That Were Pending.RENO, Nev. -- ArTec, Inc., (Pink Sheets: ATKJ) A Pharmaceutical Company announces completing its patent goals and receiving the final patents from Canada and Western Europe Western Europe The countries of western Europe, especially those that are allied with the United States and Canada in the North Atlantic Treaty Organization (established 1949 and usually known as NATO). . On August 13, 2003, the Western European Patent consisting of United Kingdom, France, Spain, Germany and Italy was issued. On May 11, 2004, the patent from Canada was issued. The goals accomplished consist of five final Patents that ArTec, Inc. will utilize: 1. Canada patent issued May 11, 2004, registration number 2,293,821. 2. Western Europe patent issued August 13, 2003, registration number 0,991,773. 3. United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. patent issued August 14, 2001, registration number 6,274,356. 4. South Korea patent issued October 29, 1998, registration number 173362. 5. Japan patent issued June 12, 1998, registration number 2,790,447. Dr. Tai Ho Chung, M.D. Ph.D., Principal Partner and Scientific Advisor for ArTec, Inc. denotes "that having acquired, all five patents now allows ArTec, Inc. to focus on US FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. submission." Furthermore, he is encouraged by the fact that research is complete (Finished Product) and there have been no adverse side effects Side effects Effects of a proposed project on other parts of the firm. in human and mice studies using Tubercin on CANCER. Upon raising funds, ArTec, Inc. will move quickly into US FDA submission. What is Tubercin? The United States Patent issued August 14, 2001, states in the abstract summary the following: "A carbohydrate complex, which is a mixture of low molecular-weight polysaccharides of an arabinomannan structure extracted from Mycobacterium tuberculosis Mycobacterium tuberculosis n. Tubercic bacillus. Mycobacterium tuberculosis , is highly effective in treating various cancer patients without incurring any adverse side effects." For further information, the US Patent and Trademark Offices's Official web site can be retrieved from ArTec, Inc.'s web site at www.artec-inc.net. Forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. in this press release, the company cautions the investors, involve risks and uncertainties pursuant to the "Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. " provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. In addition, the company cautions investors that it undertakes no obligations or responsibilities to publicly update these forward-looking statements to reflect Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. ArTec, Inc. A Pharmaceutical Company whose goal is to improve the quality of life! |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion